Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01345019 · OUTCOME

Percentage of Participants Who Died

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma · Source last updated 2022-11-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.

Analysis population: All randomized participants

Groups in this outcome

Zoledronic Acid

Participants randomized to receive zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaneously once every 4 weeks in the double-blind treatment phase.

Denosumab

Participants randomized to receive denosumab 120 mg subcutaneously plus placebo to zoledronic acid intravenously once every 4 weeks in the double-blind treatment phase.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Zoledronic Acid859
Denosumab859

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Zoledronic Acid15.0Not reported12.617.4Not reported
Denosumab14.1Not reported11.816.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        12.6
        upper Limit
        17.4
        value
        15.0
      2. group Id
        OG001
        lower Limit
        11.8
        upper Limit
        16.4
        value
        14.1
denoms
  1. counts
    1. group Id
      OG000
      value
      859
    2. group Id
      OG001
      value
      859
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants randomized to receive zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaneously once every 4 weeks in the double-blind treatment phase.
    id
    OG000
    title
    Zoledronic Acid
  2. description
    Participants randomized to receive denosumab 120 mg subcutaneously plus placebo to zoledronic acid intravenously once every 4 weeks in the double-blind treatment phase.
    id
    OG001
    title
    Denosumab
param Type
NUMBER
population Description
All randomized participants
reporting Status
POSTED
time Frame
From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
title
Percentage of Participants Who Died
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice